---
title: Radiographic and visual response to the type II RAF inhibitor tovorafenib in
  children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial
date: '2024-12-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39700439/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241220170926&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Tovorafenib demonstrated anti-tumor activity in relapsed/refractory
  BRAF-altered OPG across radiological assessment criteria and was generally well
  tolerated. Importantly, vision remained stable or improved in most ...'
disable_comments: true
---
CONCLUSIONS: Tovorafenib demonstrated anti-tumor activity in relapsed/refractory BRAF-altered OPG across radiological assessment criteria and was generally well tolerated. Importantly, vision remained stable or improved in most ...